ASCO 2024 | Recent progress in managing brain metastasis in breast cancer
Gaia Griguolo, MD, University of Padova, Padova, Italy, provides updates on treating brain metastases in patients with breast cancer. Patients with HER2-positive breast cancer have promising options, as evidenced in the HER2CLIMB trial (NCT02614794), which assessed the addition of tucatinib to trastuzumab and capecitabine, as well as other trials assessing trastuzumab deruxtecan. Additional trials are also showing encouraging intercranial efficacy in the HER2-negative setting. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Gilead Sciences; Menarini; Seagen
Speakers’ Bureau – Lilly; MSD
Travel, Accommodations, Expenses – Amgen; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer
